Holtsclaw v. Auxilium Pharmaceuticals, Inc.

  1. November 16, 2017

    Auxilium Not Liable For Man's Heart Attack, Ill. Jury Finds

    An Illinois federal jury said Thursday that Auxilium's Testim did not cause a man's heart attack, handing the drugmaker a victory in its first trial in the multidistrict litigation over testosterone replacement therapy drugs.

  2. November 15, 2017

    Auxilium's First Testosterone Bellwether Heads To Jury

    Auxilium knew that its testosterone replacement therapy drug Testim was not approved for men whose low testosterone was caused by their age but it promoted the drug for them anyway, turning their lives into "a vast experiment," attorneys for a Testim user told an Illinois federal jury Wednesday.

  3. November 07, 2017

    Heart Attack Not Worth Testim's Benefits, Patient Testifies

    The improved energy he got from using Auxilium's Testim was not worth the heart attack that nearly cost him his life, the plaintiff in the first bellwether suit against the drug company under the multidistrict litigation over testosterone replacement therapy products told an Illinois federal jury Tuesday.

  4. November 06, 2017

    Auxilium Ignored FDA's Limits On Testim's Use, Jury Told

    Attorneys for a man who had a heart attack after using Auxilium Pharmaceuticals Inc.'s product Testim told an Illinois federal jury their client suffered after the company repeatedly ignored U.S. Food and Drug Administration guidance about what Testim was safe to treat.

  5. November 03, 2017

    Auxilium Bellwether Latest Test For Testosterone Therapy Ads

    Auxilium Pharmaceuticals LLC is the second drugmaker to face a jury in the testosterone replacement therapy multidistrict litigation in Illinois federal court, with the first bellwether against the company over its alleged misrepresentations of what Testim is safe to treat set to go forward Monday.